Search clinical trials for: Extended release tacrolimus

Total 7149 results

Heleen Grootjans
Chiesi Farmaceutici S.p.A.

Recruiting

Trial Comparing Immediate Versus Extended Release Tacrolimus; Reducing Calcineurin Inhibitor Related Toxicity in Lung Transplantation Patients (REVOLUTION)

Lung Transplant; Complications

Netherlands
University of California, Los Angeles
Veloxis Pharmaceuticals

Active, not recruiting

Envarsus XR® in Adolescent Renal Transplant Recipients (EnvarsusXR)

Kidney Transplantation | Renal Transplantation | Grafting, Kidney

United States
University of Minnesota

Completed

Comparison of the Cognitive and Motor Effects of Treatment Between an Immediate- and Extended-release Tacrolimus (Envarsus® XR) Based Immunosuppression Regimen in Kidney Transplant Recipients

Kidney Transplant Failure and Rejection

United States
NYU Langone Health

Completed

Envarsus XR in Lung Transplant

Lung Transplant

United States
University of British Columbia
Paladin Labs Inc.

Recruiting

Tacrolimus Associated Tremors in Liver Transplantation: Immediate-Release Versus Extended-Release Formulations (LCP-TAC)

Liver Transplantation | Neurotoxicity | Tremor | Tacrolimus | Immunosuppression

Canada
The Methodist Hospital Research Institute
Veloxis Pharmaceuticals

Withdrawn

Evaluation of Anti-rejection Drug, Tacrolimus, in African-Americans With Kidney Transplant

Acute Rejection of Renal Transplant | Kidney Disease, End-Stage | Donor Specific Antibodies
Cedars-Sinai Medical Center
Veloxis Pharmaceuticals

Active, not recruiting

Comparison of Tacrolimus Extended-Release (Envarsus XR) to Tacrolimus Immediate-Release in HLA Sensitized Kidney Transplant Recipients

Kidney Transplant Rejection

United States
Methodist Healthcare

Completed

Envarsus XL Immunosuppression Following Liver Transplantation

Recipients of Liver Transplant

United States
Hangzhou Highlightll Pharmaceutical Co., Ltd

Completed

Evaluation of TLL-018 Extended and Immediate Release Formulation for Bioequivalence Testing in Healthy Chinese Subjects

Atopic Dermatitis

China
Luye Pharma Group Ltd.
Shandong Luye Pharmaceutical Co., Ltd.

Completed

Dose-Finding Clinical Trial to Evaluate the Efficacy and Safety of LY03005 Extended-release Tablets in the Treatment of Major Depressive Disorder (MDD)

Major Depressive Disorder

China
Newark Beth Israel Medical Center

Unknown

Once-a-day Tacrolimus Conversion Study: The OneTAC Trial (OneTAC)

Heart Failure

United States
AstraZeneca

Withdrawn

A Study to Compare the Pharmacokinetics of Different Formulations of AZD9977 and the Influence of Food in Healthy Male Subjects

Healthy Male Subjects | Pharmacokinetics | Safety | Food Effect

United Kingdom
Georgetown University

Terminated

Envarsus XR in African American Renal Transplant Recipients (EXR)

Renal Transplant Recipients

United States
University of Illinois at Chicago
Astellas Pharma US, Inc.

Completed

A Pharmacokinetic Analysis of Tacrolimus ER Dosing in Obese Kidney Transplant Recipients (Tacrolimus ER)

Kidney Transplantation

United States
UMC Utrecht

Completed

Extended Release Tacrolimus (Advagraf®) in Severe Adult Atopic Dermatitis Patients

Atopic Dermatitis

Netherlands
Ultragenyx Pharmaceutical Inc

Completed

Safety and Pharmacokinetics of Sialic Acid Tables in Patients With Hereditary Inclusion Body Myopathy (HIBM)

Hereditary Inclusion Body Myopathy (HIBM)

United States
Roy D. Bloom, MD
Veloxis Pharmaceuticals

Recruiting

Pulse Wave Velocity, Tacrolimus Time in Therapeutic Range and CV in African American Kidney Transplants (PTAAK)

Kidney Transplant; Complications

United States
Lorenzo Gallon

Completed

Extended Release Tacrolimus vs. Twice-Daily Tacrolimus

End Stage Renal Disease | Rejection of Renal Transplant

United States
Columbia University
Veloxis Pharmaceuticals

Active, not recruiting

Envarsus on the Effect of Total Tacrolimus Dose/Trough Level Ratio on Renal Function (eGFR) in Kidney Transplantation

Renal Transplant Rejection | Kidney Transplant Failure and Rejection

United States
University of Alabama at Birmingham

Completed

Conversion to Envarsus Post Kidney Transplant Protects Against BK Infection

Renal Transplant Infection

United States
Murdoch Childrens Research Institute

Recruiting

Minimising Adverse Drug Reactions and Verifying Economic Legitimacy in Children (MARVEL-PIC) (MARVEL-PIC)

Neoplasms | Bone Marrow Transplantation

Australia
Poitiers University Hospital
Chiesi Farmaceutici S.p.A.

Terminated

Prospective Cohort of Kidney Transplanted Patients Receiving an Extended Releasing Tacrolimus-Everolimus Association

Immunosuppression | Kidney Transplant

France
Luye Pharma Group Ltd.

Completed

A Study to Evaluate the Efficacy and Safety of Ansofaxine Hydrochloride Extended-release Tablets in the Treatment of Major Depressive Disorder (MDD)

Major Depressive Disorder (MDD)

China
Boehringer Ingelheim

Completed

Relative Bioavailability of BI 207127 Trial Formulation II Prototypes Versus BI 207127 Trial Formulation I in Healthy Volunteers

Healthy
Nantes University Hospital
Chiesi Farmaceutici S.p.A.

Completed

PK Study in Diabetic Transplant récipients : From Twice-daily Tacrolimus to Once-daily Extended-release Tacrolimus (SPK-PK)

Diabetes | Kidney Transplantation | Pancreas Transplantation

France
Ultragenyx Pharmaceutical Inc

Terminated

A Study to Evaluate the Safety of Aceneuramic Acid Extended Release (Ace-ER; UX001) Tablets in Glucosamine (UDP-N-acetyl)-2-Epimerase (GNE) Myopathy (GNEM) (Also Known as Hereditary Inclusion Body Myopathy [HIBM]) Patients With Severe Ambulatory Impairment

Hereditary Inclusion Body Myopathy | GNE Myopathy | Inclusion Body Myopathy 2 | Distal Myopathy With Rimmed Vacuoles | Distal Myopathy, Nonaka Type | Quadriceps Sparing Myopathy

Canada, United States, Bulgaria
University of Colorado, Denver

Terminated

Immunosuppressant Medication Dosed Daily After Kidney Transplant

Medication Adherence | Kidney Transplant Rejection

United States
Ultragenyx Pharmaceutical Inc

Terminated

Study to Evaluate the Safety and Efficacy of Aceneuramic Acid Extended-Release (Ace-ER) Tablets in Patients With Glucosamine (UDP-N-acetyl)-2-epimerase Myopathy (GNEM) or Hereditary Inclusion Body Myopathy (HIBM)

Hereditary Inclusion Body Myopathy | GNE Myopathy | Distal Myopathy With Rimmed Vacuoles | Distal Myopathy, Nonaka Type | Quadriceps Sparing Myopathy

United States, Canada, United Kingdom, Israel, Italy, Bulgaria, France
Yonsei University

Completed

Study to Evaluate the Safety and Efficacy of Extended Release Tacrolimus (Advagraf®) + Sirolimus (Rapamune®), Versus Extended Release Tacrolimus (Advagraf®) + Mycophenolate Mofetil in Kidney Transplant Patients

Kidney Transplant Patients

Korea, Republic of
Cedars-Sinai Medical Center
Astellas Pharma Inc

Completed

Trial to Evaluate Safety and Tolerability of Tacrolimus Extended-Release (Astagraf XL) in Human Leukocyte Antigen (HLA) Sensitized Kidney Transplant Recipients

End Stage Renal Disease

United States
Astellas Pharma Inc
Astellas Pharma Korea, Inc.

Completed

Pharmacokinetics of Tacrolimus in Liver Transplantation Patients Treated With Prograf and Modified Release Tacrolimus

Liver Transplantation

Korea, Republic of
Ultragenyx Pharmaceutical Inc

Completed

A Phase 2 Study to Evaluate the Dose and Pharmacodynamic Efficacy of Sialic Acid-Extended Release (SA-ER) Tablets in Patients With GNE Myopathy or Hereditary Inclusion Body Myopathy (GNE Myopathy)

Hereditary Inclusion Body Myopathy | GNE Myopathy

United States, Israel
University Health Network, Toronto
Canadian Society of Hospital Pharmacists

Withdrawn

Dosing Intervals of Opioid Medication for Chronic Pain

Chronic Pain

Canada
Hadassah Medical Organization

Completed

Efficacy of Sialic Acid GNE Related Thrombocytopenia (SA-thrombo)

Thrombocytopenia
Ultragenyx Pharmaceutical Inc

Completed

Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Sialic Acid in Patients With Glucosamine (UDP-N-acetyl)-2-epimerase Myopathy (GNEM) or Hereditary Inclusion Body Myopathy (HIBM) (GNEM)

Hereditary Inclusion Body Myopathy | GNE Myopathy | Distal Myopathy With Rimmed Vacuoles | Distal Myopathy, Nonaka Type

United States, Canada, United Kingdom, Israel, Italy, Bulgaria, France
GlaxoSmithKline

Completed

Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy In Subjects With Mild To Moderate Alzheimer's Disease (REFLECT-3)

Alzheimer's Disease

United States, Australia, Spain, Bulgaria, Poland, Germany, Philippines, Singapore, Belgium, Canada, Hong Kong, Korea, Republic of, Finland, Slovenia, Czechia, France, South Africa, Sweden, Netherlands, Malaysia, United Kingdom, S...
Yale University
Veloxis Pharmaceuticals

Recruiting

Assessment of Cognitive Function Before and After Conversion From Immediate Release Tacrolimus to Envarsus XR.

Kidney Transplant; Complications

United States
GlaxoSmithKline

Terminated

Crossover Study to Evaluate the Comparative Bioavailability of Two Fixed Dose Combination Tablet Formulations of Extended Release Metformin and Extended Release Glimepiride in Health Volunteers

Diabetes Mellitus, Type 2

Australia
LG Life Sciences

Unknown

BE Study of the Combinations of Gemigliptin 50mg and Metformin HCl Extended Release 2000mg in Comparison to Each Component Administered Alone

Healthy

Korea, Republic of
LG Life Sciences

Completed

BE Study of the Combinations of Gemigliptin 50mg and Metformin HCl Extended Release 500mg in Comparison to Each Component Administered Alone

Healthy

Korea, Republic of
LG Life Sciences

Completed

BE Study of the Combinations of Gemigliptin 50mg and Metformin HCl Extended Release 1000mg in Comparison to Each Component Administered Alone

Healthy

Korea, Republic of
Temple University
Veloxis Pharmaceuticals

Completed

Dosing Strategies for de Novo Once-daily Extended Release Tacrolimus (LCPT) in Kidney Transplant Recipients

Kidney Transplant

United States
ApoPharma

Completed

Comparison of Deferiprone Extended Release Tablets and Ferriprox Immediate Release Tablets in Healthy Volunteers

Healthy

Canada
Johns Hopkins University
Baylor College of Medicine; National Heart, Lung, and Blood Institute (NHLBI); Temple University

Not yet recruiting

Metformin IN Asthma for Overweight and Obese Individuals (MINA)

Asthma | Overweight and Obesity | Asthma Chronic
Terran Biosciences Australia Pty Ltd

Recruiting

A Study of Idazoxan in Healthy Participants

Healthy

Australia
Sun Yat-sen University

Completed

Efficacy and Safety of Tacrolimus Sustained-release Capsules in Induction Treatment in Refractory Lupus Nephritis

Nephritis, Lupus

China
Chemi S.p.A.

Completed

Extended-release of Octreotide (LF-PB) for the Treatment of Seroma

Seroma

Italy
Janssen-Cilag Ltd.,Thailand

Terminated

Extended-Release Oxybutynin for the Treatment of Neurogenic Detrusor Overactivity (RONDO)

Detrusor Function, Overactive

Thailand
University of Arizona
National Cancer Institute (NCI)

Recruiting

Metformin for the Prevention of Oral Cancer in Patients With Oral Leukoplakia or Erythroplakia

Oral Leukoplakia | Erythroplakia

United States, Canada
National Cancer Institute (NCI)

Recruiting

Metformin for Chemoprevention of Lung Cancer in Overweight or Obese Individuals at High Risk for Lung Cancer

Lung Carcinoma

United States, Canada

3

Subscribe